08247 BIOSINO BIO-TEC
- 0.590
- 0.0000.00%
BIOSINO BIO-TEC News
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
China Securities Co., Ltd.: Q2 albumin batch issuance is the same as last year, and hepatitis B batch issuance has resumed growth.
The blood product industry is expected to maintain steady growth in the first half of 24H1. In the second half of the year, the industry is expected to continue the tight supply and demand pattern. The leading companies in the industry are expected to achieve continuous increase in plasma collection and profitability, and have more competitive advantages.
Biosino Bio-Tec (08247): He Xin was appointed as an independent non-executive director.
Biosino Bio-Tec (08247) announced that the appointment of He Xin as an independent non-executive director, as well as a member of the audit committee, nomination committee and remuneration committee, has been approved by the shareholders at the anniversary general meeting and will take effect on June 28, 2024. In addition, Fan Hua has been appointed as a supervisor to replace Li Jifeng, effective from June 28, 2024, after gaining approval from the shareholders at the anniversary general meeting.
Benign Growth For Biosino Bio-Technology and Science Incorporation (HKG:8247) Underpins Stock's 26% Plummet
Biosino Bio-Tec (08247) recommends appointing Fan Hua as a shareholder representative supervisor.
Biosino Bio-Tech (08247) announced that He Xin, who holds approximately 7.83% of the company's issued share capital...
Biosino Bio-Technology and Science Incorporation (HKG:8247) Shares Fly 68% But Investors Aren't Buying For Growth
Zhongsheng Beikong Biotechnology (08247.HK): Li Jifeng Resigns as Shareholder Representative Supervisor and Chairman of the Supervisory Board
Gelonghui, April 26, 丨 Zhongsheng Beikong Biotechnology (08247.HK) announced that on April 26, 2024, Li Jifeng has resigned as the representative supervisor of the company's shareholders and the chairman of the company's board of supervisors due to other work arrangements.
Zhongsheng Beikong Biotechnology (08247) announced its 2023 annual results. Shareholders should account for a loss of 11.648 million yuan
Zhongsheng Beikong Biotechnology (08247) announced its annual results for the year ended December 31, 2023, with revenue reaching...
BIOSINO BIO-TEC: Annual Report 2023
BIOSINO BIO-TEC: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED 31 DECEMBER 2023
Zhongsheng Beijing Holdings Biotechnology (08247) issued a profit warning. The net loss for the year is expected to increase from 18 million yuan to 22 million yuan over the same period last year
According to the Zhitong Finance App, Zhongsheng Beijing Holdings Biotechnology (08247) issued an announcement. It is expected that the Group will have a net loss of RMB 18 million to RMB 22 million for the year ended December 31, 2023, while net profit of about RMB 14.202 million for the year ended December 31, 2022. According to the announcement, the expected losses during the reporting period were mainly due to changes in domestic and foreign public health prevention and control policies, a decline in market demand; and a decrease in the Group's gross profit due to falling product prices due to centralized procurement in the industry; and the Group's superior products (such as flow cytometry and
BIOSINO BIO-TEC: PROFIT WARNING
Little Excitement Around Biosino Bio-Technology and Science Incorporation's (HKG:8247) Revenues As Shares Take 31% Pounding
Zhongsheng Beikong Biotechnology (08247) released the first three quarter results, and shareholders accounted for losses of 5.993 million yuan
According to the Zhitong Finance App, Zhongsheng Beikong Biotechnology (08247) released results for the nine months ended September 30, 2023, with operating income of 2106 million yuan (RMB, same below), a year-on-year decrease of 23.6%; parent company owners accounted for losses of 5.993 million yuan, profit for the same period last year; basic loss of 0.041 yuan per share. During the reporting period, the company completed a total of 42 types of II products, including the glycated serum protein assay kit (NBT method), and 7 Class III products, including the herpes simplex virus type 1 IgG antibody test kit (chemiluminescence method), were changed and registered. α-L-
BIOSINO BIO-TEC: Third Quarterly Report 2023
BIOSINO BIO-TEC: THIRD QUARTERLY RESULTS ANNOUNCEMENT FOR THE THREE MONTHS AND NINE MONTHS ENDED 30 SEPTEMBER 2023
Zhongsheng Beikong Biotechnology (08247): Yang Peng appointed as non-executive director and vice chairman
Zhongsheng Beikong Biotechnology (08247) announced that Mr. Yang Peng has been appointed as the company's non-executive director and vice chairman,...
BIOSINO BIO-TEC: Interim Report 2023
BIOSINO BIO-TEC: INTERIM RESULTS ANNOUNCEMENTFOR THE THREE MONTHS AND SIX MONTHS ENDED 30 JUNE 2023
Risks Still Elevated At These Prices As Biosino Bio-Technology and Science Incorporation (HKG:8247) Shares Dive 38%
Analysis
Price Target
No Data
